Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Proxy Contest (April 2020)
44 slides from Regeneron Pharmaceuticals's proxy contest presentation, Apr 24, 2020
Slide 1: More Science, More Impact: 2019 Annual Report
MORE SCIENCE, MORE IMPACT 2019 ANNUAL REPORT
Slide 2: Letter to shareholders: COVID-19 response
As 2020 began, the world was presented record of success with infectious these programs as quickly as possible with a major crisis as the SARS-CoV-2 diseases like Ebola, we are optimistic over the coming weeks and months. (COVID-19) pandemic spread across that we can make a meaningful and the globe.
Slide 3: Our business is solid, and 2019 was a year of tremendous progress
outside the U.S. of $2.9 billion, bringing became profitable for the first time in 2019, OUR BUSINESS IS SOLID, EYLEA’s total global net product sales and we took important additional steps AND 2019 WAS A YEAR to $7.5 billion, a 12 percent increase compared to 2018. These figures show to strengthen
Slide 4: VelociSuite technologies and pipeline progress
multiple bispecific antibodies into the the novel coronavirus and hope for clinic, including the first in a whole new similar success. class of co-stimulatory bispecifics, which 20+ position us to become a leader in this All of this important research and emerging field. We continue to explore groun
Slide 5: Letter signatories: Vagelos, Schleifer, Yancopoulos
February 2020. We are also applying our 2019 was a busy and successful year for genetics and biology expertise to explore Regeneron, and we believe 2020 will be new modalities that are complementary even more impactful. We will innovate P. ROY VAGELOS M.D. to our world-class therapeutic antibodies.
Slide 6: 2019 By the Numbers
2019 30M 20+ BY THE NUMBERS 13 U.S. and European regulatory doses of EYLEA administered from launch through early 2020 investigational medicines in clinical development approvals 80 patient advocacy and professional 8,400+ 53 countries in which we conducted trials societies engaged across patients e
Slide 7: Table of Contents
TABLE OF CONTENTS 08 25 SCIENTIFIC BREADTH CUTTING-EDGE RESEARCH AND DEPTH AND TECHNOLOGY 30 33 SCIENCE-ENABLING RESPONSIBLE BUSINESS STRATEGIES REGENERON
Slide 8: Scientific Breadth and Depth
Our Approved Medicines 09 Robust Clinical Pipeline 10 Recent Publication Highlights 11 Excellence in Retinal Diseases 13 SCIENTIFIC BREADTH AND DEPTH Broad Development in Inflammation and Allergic Diseases 15 Diverse and Flexible Immuno-oncology Approach 18 Rapid Response Approach in Infectious Dise
Slide 9: Regeneron-discovered, FDA-approved medicines
7 REGENERON-DISCOVERED, FDA-APPROVED MEDICINES 3 1 2 Please refer 2 4 to for more information on our marketed 1. Commercialized by Bayer ex-U.S. medicines, including 2. Developed and commercialized under full safety global collaboration with Sanofi 3. Commercialized by Sanofi ex-U.S., information. e
Slide 10: Robust Clinical Pipeline
ROBUST CLINICAL PIPELINE Over 20 investigational medicines in clinical development, all of which were discovered and developed in our own laboratories using our proprietary VelociSuite® technologies. PHASE 1 PHASE 2 PHASE 3 CEMIPLIMAB* REGN5459* AFLIBERCEPT SARILUMAB* GARETOSMAB AFLIBERCEPT DUPILUMA
Slide 11: Recent Publication Highlights
200+ peer-reviewed A RANDOMIZED, CONTROLLED TRIAL OF scientific publications EBOLA VIRUS DISEASE THERAPEUTICS in 2019 EFFICACY AND SAFETY OF DUPILUMAB IN PATIENTS WITH SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS DUAL BLOCKADE OF IL-4 AND IL-13 WITH DUPILUMAB, AN IL-4RĮ± ANTIBODY, ~90 citations o
Slide 12: Recent Publication Highlights (continued)
A NOVEL BISPECIFIC ANTIBODY PLATFORM A CLASS OF COSTIMULATORY CD28- TO DIRECT COMPLEMENT ACTIVITY BISPECIFIC ANTIBODIES THAT FOR EFFICIENT LYSIS OF TARGET CELLS ENHANCE THE ANTITUMOR ACTIVITY OF CD3-BISPECIFIC ANTIBODIES OF CD3-BISPECIFIC ANTIBODIES A MUCIN 16 BISPECIFIC T CELL-ENGAGING ANTIBODY FOR
Slide 13: Excellence in Retinal Disease
EXCELLENCE IN in diabetic retinopathy, a major milestone that extends the benefits of EYLEA to many additional patients. RETINAL DISEASE The initial uptake of EYLEA for diabetic retinopathy has been strong, with positive feedback from ophthalmologists. Yet tremendous unmet need EYLEA 2019 REGULATORY
Slide 14: Our hard-working IOPS team
THE PEOPLE WHO INSPIRE US OUR HARD-WORKING IOPS TEAM The pre-filled syringe for EYLEA was an eye-opening project for the Industrial Operations and Product Supply (IOPS) team. “It was important for us to get EYLEA in a pre- hydrogen peroxide for our sterilization—even filled syringe on the market so
Slide 15: Broad Development in Inflammation and Allergic Diseases
BROAD product sales of $2.3 billion in 2019. Yet even with approvals for several conditions and age groups, we are just beginning to realize the full potential of this DEVELOPMENT IN innovative medicine. In 2019, we added several new indications to DUPIXENT 2019 REGULATORY Dupixent’s label, securing
Slide 16: Patients and their families
THE PEOPLE WHO INSPIRE US PATIENTS AND THEIR FAMILIES Jake, an 18-year-old from San Diego, CA, was diagnosed with severe atopic dermatitis (AD) when he was just six-months old. During his childhood, symptoms of the disease my AD is a serious disease, but it is. Some covered up to 80 percent of his b
Slide 17: REGN3500, REGN1908-1909, REGN5713-5714-5715
Building on the expertise established with Dupixent, we have made significant strides in investigating the potential of new approaches to treating allergic and inflammatory diseases: REGN3500 REGN1908-1909 REGN5713-5714-5715 REGN3500 is an IL-33 antibody in Phase 2 trials for Cat allergy is a major
Slide 18: Diverse and Flexible Immuno-oncology Approach
DIVERSE AND In 2019, our PD-1 inhibitor Libtayo became the standard of care for advanced cutaneous squamous cell carcinoma (CSCC) generating global net product sales of $194 million.1 FLEXIBLE The rapid transformation of this treatment paradigm LIBTAYO 2019 REGULATORY occurred in less than a year, u
Slide 19: Patients and their families
THE PEOPLE WHO INSPIRE US PATIENTS AND THEIR FAMILIES Unfortunately, Cathy was no stranger to skin cancer. Over the course of several decades, she had undergone multiple surgeries to remove growths of cutaneous squamous cell carcinoma (CSCC) on her head and upper body. But when one of the growths of
Slide 20: Bispecific Antibodies
BISPECIFIC ANTIBODIES Following the successful launch of Libtayo, we have In 2019, we saw progress across all three categories continued to advance multiple investigational candidates of Regeneron bispecifics. Our first CD3 bispecific to from our bispecific antibody platform. Designed to enter the c
Slide 21: Rapid Response in Infectious Diseases
RAPID RESPONSE One of our proudest moments of 2019 was learning that our investigational Ebola therapy, REGN-EB3, was so effective in preventing death compared to IN INFECTIOUS the prior antibody standard of care that the PALM clinical trial was halted early. The results, later published in The New
Slide 22: Healthcare providers on the ground
THE PEOPLE WHO INSPIRE US HEALTHCARE PROVIDERS ON THE GROUND While the city of Goma bustled around them, severe illness too late to receive effective care and Drs. Patrice Kabongo and Ian Crozier sat quietly had died the night before; this hung heavy over and intently focused on an infant in a small
Slide 23: Novel Antibodies for COVID-19
With the emergence of the novel coronavirus SARS- NOVEL ANTIBODIES FOR COVID-19 CoV-2 in late 2019 and early 2020, the Regeneron team again responded with urgency, applying our core ‘rapid response’ technologies to identify hundreds of virus- neutralizing antibodies and selecting the most potent to
Slide 24: Rare Disease and Pain Programs
RARE DISEASE AND PAIN PROGRAMS EVINACUMAB POZELIMAB GARETOSMAB FASINUMAB In mid-2019, we announced that our In patients with the ultra-rare condition Fibrodysplasia ossificans progressive (FOP) As the opioid crisis continues and the Phase 3 trial investigating evinacumab, an of paroxysmal nocturnal
Slide 25: Cutting-Edge Research and Technology
Veloci-Bi® 26 Viral Vector and Gene Therapy Technologies 26 CUTTING-EDGE Gene Silencing and siRNA 26 RESEARCH AND 28 TECHNOLOGY Regeneron Genetics Center 29 Industrial Operations and Product Supply
Slide 26: Veloci-Bi, Viral Vector and Gene Therapy, Gene Silencing and siRNA
VIRAL VECTOR AND GENE SILENCING AND siRNA GENE THERAPY TECHNOLOGIES Veloci-Bi allows us to create bispecific antibodies Regeneron’s expertise in viral vector engineering, The underlying cause of many diseases can with no linkers or artificial sequences. As gene editing and DNA repair biology synergi
Slide 27: Our science-focused collaborators
THE PEOPLE WHO INSPIRE US OUR SCIENCE-FOCUSED COLLABORATORS What happens when two like-minded and innovation-focused companies bring their expertise together on a novel challenge? Beautiful science that we hope will lead to life-changing medicine. In April 2019, we announced a broad new the details,
Slide 28: Regeneron Genetics Center
REGENERON GENETICS CENTER In 2019 and early 2020, our Regeneron Genetics Center For example, using genetic analysis, our researchers celebrated two major achievements as they worked to identified a patient subgroup that may receive further our understanding of the genetic underpinnings greater benef
Slide 29: Industrial Operations and Product Supply
INDUSTRIAL OPERATIONS AND PRODUCT SUPPLY Our IOPS teams in Rensselaer, New York, and Raheen, Ireland, continue to maintain and advance industry- leading manufacturing, quality and supply chain practices for our clinical and commercial medicines. 2019 In 2019, the team completed seven successful glob
Slide 30: Science-Enabling Business Strategies
31 SCIENCE-ENABLING BUSINESS Investing in Regeneron’s Future Sanofi Collaboration Restructurings 32 STRATEGIES
Slide 31: Investing in Regeneron's Future
INVESTING IN REGENERON’S FUTURE As we strengthen Regeneron for the future, we are not only we announced that Alnylam and Regeneron will be working diversifying our portfolio through the science we pursue but on a broad research initiative that covers the discovery, also through the strategic investm
Slide 32: Sanofi Collaboration Restructurings
SANOFI COLLABORATION RESTRUCTURINGS We have collaborated with Sanofi for more than a In addition, in the second quarter of 2020, we decade, with our highly productive partnership evolving simplified our antibody collaboration for Praluent in step with our companies’ growth and development. by restru
Slide 33: Responsible Regeneron
RESPONSIBLE Being a Responsible Corporate Citizen 34 2025 Global Responsibility Goals 37 New Environmental Targets to Help Protect and Restore the Planet 38 REGENERON
Slide 34: Being a Responsible Corporate Citizen
BEING A RESPONSIBLE CORPORATE CITIZEN SELECT 2019 HONORS Regeneron’s mission is to use the power of • RobecoSAM and S&P Dow Jones Indices: Dow science to bring new medicines to patients, Jones Sustainability World Index over and over again. We are committed to operating responsibly, communicating •
Slide 35: Responsibility strategy: three focus areas
Our responsibility strategy centers on three focus areas: the range of policies, practices and initiatives we have implemented, encompassing areas 1. Improve the lives of people with serious diseases. As such as compliance, responsible sales and a science-focused company, we operate Regeneron with m
Slide 36: Employee volunteering and STEM education
to the Regeneron Science Talent Search, the nation’s most prestigious pre-college science and mathematics competition, and our new five-year, $24-million commitment to the Regeneron International Science and Engineering Fair, the world’s largest pre-college science and engineering competition. In 20
Slide 37: Regeneron's 2025 Responsibility Goals
REGENERON’S 2025 RESPONSIBILITY GOALS IMPROVE THE LIVES OF PEOPLE FOSTER A CULTURE OF INTEGRITY BUILD SUSTAINABLE In 2019, we set global WITH SERIOUS DISEASES AND EXCELLENCE COMMUNITIES 2025 responsibility goals, which span Use the power of science to discover Cultivate a leading workplace Achieve o
Slide 38: New Environmental Targets to Help Protect and Restore the Planet
NEW ENVIRONMENTAL TARGETS TO HELP PROTECT AND RESTORE THE PLANET WATER By 2025, improve water efficiencies by implementing global water mapping strategy and water stewardship program. WASTE By 2021, achieve zero waste to landfill status at all Regeneron By 2025, develop and implement waste managemen
Slide 39: Continued Operational Growth
CONTINUED OPERATIONAL GROWTH REVENUE* FULL-TIME EMPLOYEES R&D INVESTMENT* $7.863B 7,300 8,100 $3.037B $6.711B $5.872B 6,200 $2.075B $2.186B 2017 2018 2019 2017 2018 2019 2017 2018 2019 *As reported in Regeneron’s Annual Report on Form 10-K for the year ended December 31, 2019. In the second quarter
Slide 40: Forward Looking Statements
FORWARD LOOKING STATEMENTS This report includes forward-looking statements that Products and Regeneron’s product candidates and applications; ongoing regulatory obligations and oversight involve risks and uncertainties relating to future events and research and clinical programs now underway or impa
Slide 41: Forward Looking Statements (Continued)
FORWARD LOOKING STATEMENTS (Continued) its financial projections or guidance, and and other material risks can be found in changes to the assumptions underlying Regeneron’s filings with the U.S. Securities those projections or guidance; the potential and Exchange Commission, including for any licens
Slide 42: Corporate Information
CORPORATE INFORMATION Common Stock and Related Matters Our Common Stock is traded on The As of April 14, 2020, there were 170 shareholders of record of our Common Stock and 16 shareholders of record of our Class A Stock. NASDAQ Global Select Market under The closing sales price for the Common Stock
Slide 43: Trademarks
REGENERON®, Science to Medicine®, Regeneron Genetics Center® and the following are registered trademarks of Regeneron Pharmaceuticals, Inc.: ARCALYST®, EYLEA®, Libtayo® (in the U.S.), VelociGene®, VelocImmune®, Veloci-Bi®, VelociMab®, VelociMouse®, VelociSuite® and ZALTRAP®. Praluent®, Dupixent® and
Slide 44: Design by addison.com
Design by addison.com REGENERON
Regeneron Pharmaceuticals — Proxy Contest (April 2020) on 6ix